Developer docs
API playgroundTry for free, no card

Search company profiles

Endologix

Full company profile

uuid0004aa3

Namestring
Endologix
Legal namestring
Endologix LLC
Websiteurl
endologix.com
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Endologix is a US-headquartered, privately held medical device company (wholly owned by Deerfield Management since October 2020) that develops and manufactures minimally invasive treatments for vascular disease, with a primary focus on abdominal aortic aneurysm (AAA) repair and peripheral arterial disease (PAD). The company's commercial portfolio centers on three platforms: the AFX2 Endovascular AAA System (bifurcated unibody design with ActiveSeal technology), the ALTO Abdominal Stent Graft System (Adaptive Sealing Technology, 13F delivery profile, and a 7mm neck-length indication for complex anatomies), and the DETOUR System (acquired via PQ Bypass in 2021, providing the first fully percutaneous transmural arterial bypass for long femoropopliteal lesions). In May 2026, Endologix acquired the Pounce Thrombectomy System from Surmodics, adding a mechanical peripheral thrombectomy platform to extend into adjacent vascular intervention indications.

The company's underlying technology relies on proprietary stent graft architectures, Nitinol-based delivery and sealing mechanisms, and a clinical evidence base of 16 trials and 2,000+ patients including two randomized controlled trials (LEOPARD and JAGUAR). Manufacturing is conducted in Irvine and Santa Rosa, California, with planned closure of a Milpitas facility in 2026 as part of post-bankruptcy restructuring. Endologix operates through subsidiaries in the Netherlands, Italy, and Poland, with sales coverage also in Germany, the UK, and Belgium.

Endologix generates revenue primarily through direct enterprise field sales of medical devices to hospitals and healthcare facilities, supported by in-procedure clinical support, Centers of Excellence training, and a reimbursement support center. Products are reimbursed under existing hospital and CMS payment frameworks (including a 2023 Transitional Pass-Through Payment for DETOUR). Customer segments include vascular surgeons, interventional cardiologists, and interventional radiologists performing EVAR, PTAB, and peripheral thrombectomy procedures, with targeted sub-segments in complex anatomies (short necks, small access vessels) and female EVAR patients historically underserved by conventional devices.

Short descriptiontext

Endologix is a US-headquartered, Deerfield-owned medical device company developing minimally invasive endovascular stent grafts and percutaneous bypass systems for abdominal aortic aneurysm repair and peripheral arterial disease, sold directly to hospitals and vascular specialists.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
endovascular aneurysm repair, aortic stent grafts, peripheral arterial disease, mechanical thrombectomy systems, vascular medical devices
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Vascular Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Endologix generates revenue through the sale of medical devices to hospitals and healthcare facilities. Commercial products include AFX2 Endovascular AAA System, ALTO Abdominal Stent Graft System, DETOUR System, and Pounce Thrombectomy System. Devices are sold directly to healthcare providers who perform procedures on patients.

endologix.com
2Professional Education Services
TypeProfessional Services
Description

Endologix provides professional education and training programs for physicians including webinars, Centers of Excellence training, and VR procedural training sessions. These programs support adoption of company products.

endologix.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Medical devices for vascular procedures
ModelOtherBilling cadenceMulti-year contract
Notes

Product pricing not publicly disclosed. Devices sold to hospitals and healthcare facilities. Reimbursement and insurance coverage varies by payer.

endologix.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1DETOUR
Description

Percutaneous transmural arterial bypass (PTAB) system for treatment of long femoropopliteal lesions

endologix.com
+3 more records
Core offering1 text field

Endologix develops and manufactures minimally invasive medical devices for treating vascular disorders, including endovascular aneurysm repair (EVAR) systems for abdominal aortic aneurysms (AAA) and the DETOUR System for peripheral arterial disease (PAD). The company sells its products directly to hospitals and healthcare facilities, complemented by professional education, VR procedural training, and reimbursement support services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 97.2% Freedom from secondary intervention due to graft occlusion at 5 years (ALTO/ENCORE)
+5 more records
Product overview1 text field

Endologix is a medical device company offering a portfolio of vascular intervention products. The portfolio centers on three commercial platforms: the DETOUR System (percutaneous transmural arterial bypass for long-segment PAD), the ALTO Abdominal Stent Graft System (EVAR with Adaptive Sealing Technology), and the AFX2 Endovascular AAA System (bifurcated unibody design EVAR). The company recently expanded its portfolio through the acquisition of the Pounce Thrombectomy System (FDA-cleared mechanical thrombectomy). Endologix also provides professional education services including VR procedural training and health economics/reimbursement support. The company operates under ownership of Deerfield Management with offices and manufacturing in California.

Product and service6 records
1DETOUR System
CategoryPeripheral Arterial Disease Therapy
Description

First fully percutaneous transmural arterial bypass (PTAB) therapy for treating long-segment femoropopliteal lesions in PAD patients. Creates a femoropopliteal bypass routed through the femoral vein under fluoroscopic guidance. For vascular surgeons and interventionalists treating PAD patients who are suboptimal candidates for surgical bypass.

2ALTO Abdominal Stent Graft System
CategoryAbdominal Aortic Aneurysm Treatment
Description

EVAR device featuring exclusive Adaptive Sealing Technology that molds in-situ to the patient's specific aortic neck anatomy. Features the lowest profile device (13F inner diameter delivery system) and shortest neck length indication (7mm) for treating infrarenal abdominal aortic aneurysms with specialized anatomies. For vascular surgeons performing EVAR on AAA patients with challenging anatomy.

3AFX2 Endovascular AAA System
CategoryAbdominal Aortic Aneurysm Treatment
Description

Endovascular aneurysm repair (EVAR) device featuring a bifurcated unibody design that preserves native bifurcation and separates graft fixation from sealing zone. Utilizes ActiveSeal technology that conforms to the aortic wall. For vascular surgeons performing EVAR on AAA patients.

4Pounce Thrombectomy System
CategoryPeripheral Vascular Thrombectomy
Description

FDA-cleared fully mechanical thrombectomy system for non-surgical removal of thrombi and emboli from peripheral arteries. Built around proprietary dual-basket technology and a nitinol collection funnel, the system supports procedural simplicity without reliance on capital equipment, thrombolytics, or aspiration. Includes Pounce LP, Pounce, and Pounce XL configurations for various peripheral arterial vessel sizes. For interventionalists performing peripheral thrombectomy.

5VR Procedural Training
CategoryProfessional Education and Training
Description

Immersive virtual reality training programs for physicians to practice procedural steps safely. Supports the full Endologix portfolio including DETOUR System, ALTO Abdominal Stent Graft System, and AFX2 Endovascular AAA System procedures. Demonstrated 230% improvement compared to traditional training methods. For vascular surgeons and interventionalists learning Endologix procedures.

6DETOUR Health Economics and Reimbursement Support
CategoryReimbursement Support Service
Description

Comprehensive support including facility coding and reimbursement, physician coding and reimbursement, patient access, and claims review and assistance for the DETOUR System. For healthcare facilities and providers deploying the DETOUR System.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-18
Description

Endologix acquired the Pounce Thrombectomy System from Surmodics, Inc. The FDA-cleared mechanical thrombectomy platform uses proprietary dual-basket technology and nitinol collection funnel for non-surgical removal of thrombi and emboli from peripheral arteries. Transaction closed May 18, 2026. A core group of Surmodics employees supporting Pounce transitioned to Endologix.

2Steve Deitsch
Strategic tierMinorTypeOthersAnnounced on2026-05-07
Description

Over 25 years of healthcare and medtech experience. Currently CEO of Caristo Diagnostics. Previously CFO of OrganOx, which he led through its $1.5 billion sale to Terumo Corporation in 2025 - the largest spinout exit in University of Oxford's history.

endologix.com
3Scott Huennekens
Strategic tierMinorTypeOthersAnnounced on2025-07-07
Description

Former CEO of Volcano Corp. joined Endologix Board of Directors. Awarded EY's Entrepreneur of the Year award in 2010 and recognized by Goldman Sachs as one of the 100 most intriguing entrepreneurs.

endologix.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-04-01
Description

Endologix acquired PQ Bypass, Inc., adding the DETOUR System and TORUS Stent Graft to the company's product pipeline. The DETOUR System is a first-ever fully percutaneous transmural arterial bypass therapy for PAD.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global medtech leader with the Endurant abdominal stent graft system and a broad peripheral vascular portfolio including IN.PACT drug-coated balloons and HawkOne atherectomy. Directly competes with Endologix in EVAR and is the entrenched market leader across vascular surgery.

2Cook Medical
TypeDirect peer
Description

Manufacturer of the Zenith abdominal and thoracic aortic stent graft systems, directly competing with Endologix in EVAR for AAA. Long-established player with deep vascular surgeon relationships globally.

TypeBroad incumbent
Description

Through Vascutek and Bolton, Terumo offers the Relay thoracic and abdominal stent graft systems that compete directly with Endologix's ALTO and AFX2, particularly in complex anatomies and international markets.

TypeEmerging player
Description

Developer of the Auryon atherectomy system and AlphaVac mechanical thrombectomy system, directly competing with Endologix's Pounce platform and PAD portfolio in peripheral vascular intervention.

TypeEmerging player
Description

Specialty cardiovascular and vascular surgery company offering aortic stent grafts (formerly CryoLife) that directly compete with Endologix in complex AAA and thoracic aortic disease, particularly for hostile anatomies.

TypeEmerging player
Description

Former owner of the Pounce Thrombectomy System now acquired by Endologix. Surmodics continues to develop drug-coated balloon and surface-coating technologies relevant to vascular intervention and overlaps with Endologix in the broader peripheral space.

7Jandel Laboratories / Inari Medical
TypeEmerging player
Description

Acquired by Stryker in 2025, Inari Medical developed the FlowTriever system for venous thromboembolism and ClotTriever for thrombectomy, representing an adjacent emerging player in the mechanical thrombectomy category where Endologix's Pounce now competes.

TypeBroad incumbent
Description

Major vascular device manufacturer offering XIENCE, Supera, and other peripheral products that overlap with Endologix's PAD and AAA portfolios, particularly through hospital purchasing agreements and integrated sales coverage.

TypeDirect peer
Description

Developer of the Indigo mechanical thrombectomy system for peripheral and neurovascular indications, directly competing with the newly acquired Pounce Thrombectomy System in peripheral arterial thrombus removal.

TypeDirect peer
Description

Manufacturer of the Gore Excluder AAA Endoprosthesis and Gore Viabahn endoprosthesis, one of the closest direct competitors to Endologix's AFX2 and ALTO in EVAR and a longstanding leader in stent graft technology for aortic disease.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Endologix

Vascular Medical Devicesendologix.com

Endologix is a US-headquartered, Deerfield-owned medical device company developing minimally invasive endovascular stent grafts and percutaneous bypass systems for abdominal aortic aneurysm repair and peripheral arterial disease, sold directly to hospitals and vascular specialists.

What Endologix does

Endologix is a US-headquartered, privately held medical device company (wholly owned by Deerfield Management since October 2020) that develops and manufactures minimally invasive treatments for vascular disease, with a primary focus on abdominal aortic aneurysm (AAA) repair and peripheral arterial disease (PAD). The company's commercial portfolio centers on three platforms: the AFX2 Endovascular AAA System (bifurcated unibody design with ActiveSeal technology), the ALTO Abdominal Stent Graft System (Adaptive Sealing Technology, 13F delivery profile, and a 7mm neck-length indication for complex anatomies), and the DETOUR System (acquired via PQ Bypass in 2021, providing the first fully percutaneous transmural arterial bypass for long femoropopliteal lesions). In May 2026, Endologix acquired the Pounce Thrombectomy System from Surmodics, adding a mechanical peripheral thrombectomy platform to extend into adjacent vascular intervention indications.

The company's underlying technology relies on proprietary stent graft architectures, Nitinol-based delivery and sealing mechanisms, and a clinical evidence base of 16 trials and 2,000+ patients including two randomized controlled trials (LEOPARD and JAGUAR). Manufacturing is conducted in Irvine and Santa Rosa, California, with planned closure of a Milpitas facility in 2026 as part of post-bankruptcy restructuring. Endologix operates through subsidiaries in the Netherlands, Italy, and Poland, with sales coverage also in Germany, the UK, and Belgium.

Endologix generates revenue primarily through direct enterprise field sales of medical devices to hospitals and healthcare facilities, supported by in-procedure clinical support, Centers of Excellence training, and a reimbursement support center. Products are reimbursed under existing hospital and CMS payment frameworks (including a 2023 Transitional Pass-Through Payment for DETOUR). Customer segments include vascular surgeons, interventional cardiologists, and interventional radiologists performing EVAR, PTAB, and peripheral thrombectomy procedures, with targeted sub-segments in complex anatomies (short necks, small access vessels) and female EVAR patients historically underserved by conventional devices.

Endologix firmographics

Firmographics
Name
Endologix
Legal name
Endologix LLC
Website
https://endologix.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Endologix is a US-headquartered, Deerfield-owned medical device company developing minimally invasive endovascular stent grafts and percutaneous bypass systems for abdominal aortic aneurysm repair and peripheral arterial disease, sold directly to hospitals and vascular specialists.
Ownership category
akta.pro rank

Endologix industry classification

Industry
Product category
Vascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Endovascular aneurysm repair
  • Aortic stent grafts
  • Peripheral arterial disease
  • Mechanical thrombectomy systems
  • Vascular medical devices

Where Endologix is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Endologix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Sales: Endologix generates revenue through the sale of medical devices to hospitals and healthcare facilities. Commercial products include AFX2 Endovascular AAA System, ALTO Abdominal Stent Graft System, DETOUR System, and Pounce Thrombectomy System. Devices are sold directly to healthcare providers who perform procedures on patients.
  2. Professional Education Services: Endologix provides professional education and training programs for physicians including webinars, Centers of Excellence training, and VR procedural training sessions. These programs support adoption of company products.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMedical devices for vascular procedures

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Endologix product offering

Product offering

Core offering

Endologix develops and manufactures minimally invasive medical devices for treating vascular disorders, including endovascular aneurysm repair (EVAR) systems for abdominal aortic aneurysms (AAA) and the DETOUR System for peripheral arterial disease (PAD). The company sells its products directly to hospitals and healthcare facilities, complemented by professional education, VR procedural training, and reimbursement support services.

Product overview

Endologix is a medical device company offering a portfolio of vascular intervention products. The portfolio centers on three commercial platforms: the DETOUR System (percutaneous transmural arterial bypass for long-segment PAD), the ALTO Abdominal Stent Graft System (EVAR with Adaptive Sealing Technology), and the AFX2 Endovascular AAA System (bifurcated unibody design EVAR). The company recently expanded its portfolio through the acquisition of the Pounce Thrombectomy System (FDA-cleared mechanical thrombectomy). Endologix also provides professional education services including VR procedural training and health economics/reimbursement support. The company operates under ownership of Deerfield Management with offices and manufacturing in California.

Differentiator

Problem solved

Functional benefit

Brands

  • DETOUR: Percutaneous transmural arterial bypass (PTAB) system for treatment of long femoropopliteal lesions
  • ALTO
  • AFX2
  • Pounce

Products and services

  • DETOUR System First fully percutaneous transmural arterial bypass (PTAB) therapy for treating long-segment femoropopliteal lesions in PAD patients. Creates a femoropopliteal bypass routed through the femoral vein under fluoroscopic guidance. For vascular surgeons and interventionalists treating PAD patients who are suboptimal candidates for surgical bypass.
  • ALTO Abdominal Stent Graft System EVAR device featuring exclusive Adaptive Sealing Technology that molds in-situ to the patient's specific aortic neck anatomy. Features the lowest profile device (13F inner diameter delivery system) and shortest neck length indication (7mm) for treating infrarenal abdominal aortic aneurysms with specialized anatomies. For vascular surgeons performing EVAR on AAA patients with challenging anatomy.
  • AFX2 Endovascular AAA System Endovascular aneurysm repair (EVAR) device featuring a bifurcated unibody design that preserves native bifurcation and separates graft fixation from sealing zone. Utilizes ActiveSeal technology that conforms to the aortic wall. For vascular surgeons performing EVAR on AAA patients.
  • Pounce Thrombectomy System FDA-cleared fully mechanical thrombectomy system for non-surgical removal of thrombi and emboli from peripheral arteries. Built around proprietary dual-basket technology and a nitinol collection funnel, the system supports procedural simplicity without reliance on capital equipment, thrombolytics, or aspiration. Includes Pounce LP, Pounce, and Pounce XL configurations for various peripheral arterial vessel sizes. For interventionalists performing peripheral thrombectomy.
  • VR Procedural Training Immersive virtual reality training programs for physicians to practice procedural steps safely. Supports the full Endologix portfolio including DETOUR System, ALTO Abdominal Stent Graft System, and AFX2 Endovascular AAA System procedures. Demonstrated 230% improvement compared to traditional training methods. For vascular surgeons and interventionalists learning Endologix procedures.
  • DETOUR Health Economics and Reimbursement Support Comprehensive support including facility coding and reimbursement, physician coding and reimbursement, patient access, and claims review and assistance for the DETOUR System. For healthcare facilities and providers deploying the DETOUR System.

Quantifiable outcome

  • 97.2% Freedom from secondary intervention due to graft occlusion at 5 years (ALTO/ENCORE)
  • +5 more outcomes

Companies that use Endologix

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Endologix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Endologix partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Surmodics, Inc.coreTechnology or Integration · 18 May 2026Endologix acquired the Pounce Thrombectomy System from Surmodics, Inc. The FDA-cleared mechanical thrombectomy platform uses proprietary dual-basket technology and nitinol collection funnel for non-surgical removal of thrombi and emboli from peripheral arteries. Transaction closed May 18, 2026. A core group of Surmodics employees supporting Pounce transitioned to Endologix.
  • Steve DeitschminorOthers · 7 May 2026Over 25 years of healthcare and medtech experience. Currently CEO of Caristo Diagnostics. Previously CFO of OrganOx, which he led through its $1.5 billion sale to Terumo Corporation in 2025 - the largest spinout exit in University of Oxford's history.
  • Scott HuennekensminorOthers · 7 July 2025Former CEO of Volcano Corp. joined Endologix Board of Directors. Awarded EY's Entrepreneur of the Year award in 2010 and recognized by Goldman Sachs as one of the 100 most intriguing entrepreneurs.
  • PQ Bypass, Inc.coreTechnology or Integration · 1 April 2021Endologix acquired PQ Bypass, Inc., adding the DETOUR System and TORUS Stent Graft to the company's product pipeline. The DETOUR System is a first-ever fully percutaneous transmural arterial bypass therapy for PAD.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Endologix competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Global medtech leader with the Endurant abdominal stent graft system and a broad peripheral vascular portfolio including IN.PACT drug-coated balloons and HawkOne atherectomy. Directly competes with Endologix in EVAR and is the entrenched market leader across vascular surgery.
  • Terumo Aortic: Through Vascutek and Bolton, Terumo offers the Relay thoracic and abdominal stent graft systems that compete directly with Endologix's ALTO and AFX2, particularly in complex anatomies and international markets.
  • Abbott Vascular: Major vascular device manufacturer offering XIENCE, Supera, and other peripheral products that overlap with Endologix's PAD and AAA portfolios, particularly through hospital purchasing agreements and integrated sales coverage.

Direct peers

  • Cook Medical: Manufacturer of the Zenith abdominal and thoracic aortic stent graft systems, directly competing with Endologix in EVAR for AAA. Long-established player with deep vascular surgeon relationships globally.
  • Penumbra: Developer of the Indigo mechanical thrombectomy system for peripheral and neurovascular indications, directly competing with the newly acquired Pounce Thrombectomy System in peripheral arterial thrombus removal.
  • W. L. Gore & Associates: Manufacturer of the Gore Excluder AAA Endoprosthesis and Gore Viabahn endoprosthesis, one of the closest direct competitors to Endologix's AFX2 and ALTO in EVAR and a longstanding leader in stent graft technology for aortic disease.

Emerging players

  • AngioDynamics: Developer of the Auryon atherectomy system and AlphaVac mechanical thrombectomy system, directly competing with Endologix's Pounce platform and PAD portfolio in peripheral vascular intervention.
  • Artivion: Specialty cardiovascular and vascular surgery company offering aortic stent grafts (formerly CryoLife) that directly compete with Endologix in complex AAA and thoracic aortic disease, particularly for hostile anatomies.
  • Surmodics: Former owner of the Pounce Thrombectomy System now acquired by Endologix. Surmodics continues to develop drug-coated balloon and surface-coating technologies relevant to vascular intervention and overlaps with Endologix in the broader peripheral space.
  • Jandel Laboratories / Inari Medical: Acquired by Stryker in 2025, Inari Medical developed the FlowTriever system for venous thromboembolism and ClotTriever for thrombectomy, representing an adjacent emerging player in the mechanical thrombectomy category where Endologix's Pounce now competes.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Endologix social profiles

Digital presence

Endologix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Endologix leadership team

Management profile

Number of profiles

Profiles12 records

Endologix subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Endologix funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Endologix M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endologix

What does Endologix do?

Endologix develops and manufactures minimally invasive medical devices for treating vascular disorders, including endovascular aneurysm repair (EVAR) systems for abdominal aortic aneurysms (AAA) and the DETOUR System for peripheral arterial disease (PAD). The company sells its products directly to hospitals and healthcare facilities, complemented by professional education, VR procedural training, and reimbursement support services.

Is Endologix a public or private company?

Endologix is a private company. It is classified as private equity controlled and is currently operating.

When was Endologix founded?

Endologix was founded in 1992. It employs 501 to 1,000 people.

Where is Endologix based?

Endologix is headquartered in Irvine, United States, in the North America region.

How does Endologix make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are professional Education Services.

Who are Endologix's main competitors?

Broad incumbents on record are Medtronic, Terumo Aortic and Abbott Vascular. Direct peers are Cook Medical, Penumbra and W. L. Gore & Associates. Emerging players are AngioDynamics, Artivion, Surmodics and Jandel Laboratories / Inari Medical.

Does Endologix have an API?

No public API is recorded for Endologix.

What industry is Endologix in?

Endologix's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magSteve Deitsch Joins Endologix’s Board of DirectorsEndologix appointed Steve Deitsch to its Board of Directors. Deitsch, CEO of Caristo Diagnostics, previously led OrganOx's 2025 $1.5 billion sale to Terumo, the largest Oxford spinout exit. He will join Endologix, a vascular device company owned by Deerfield Management.BioSpace3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA DiseaseEndologix published 36-month results from the DETOUR2 trial of its PTAB system for complex femoropopliteal disease. The study of 202 patients showed 58.2% primary patency and 97.9% freedom from major amputation. The findings support the system as a minimally invasive alternative to open bypass.FinancialContent Business Page3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA DiseaseEndologix LLC announced 36-month results from the DETOUR2 clinical trial, published in the Journal of the Society for Cardiovascular Angiography and Interventions, evaluating the DETOUR System for percutaneous transmural arterial bypass in patients with complex peripheral arterial disease. The prospective, international multicenter study enrolled 202 patients across 32 clinical sites and demonstrated sustained safety with 58.2% primary patency, 97.9% freedom from major amputation, and 96.7% clinical success at 36 months. The DETOUR System offers a minimally invasive alternative to open surgical bypass for long-segment femoropopliteal lesions, with John Liddicoat, President and CEO, highlighting its potential as a meaningful advancement for treating complex PAD.Business Wire Blog3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA DiseaseEndologix published 36-month results from the DETOUR2 trial of its PTAB system for complex femoropopliteal disease. The study of 202 patients showed 58.2% primary patency and 97.9% freedom from major amputation. The findings support the system as a minimally invasive alternative for long-segment lesions.Pulse 2.0Endologix: Pounce Thrombectomy System Acquisition Expands Vascular Intervention PortfolioEndologix announced the acquisition of the Pounce Thrombectomy System from Surmodics, with the transaction closing on May 18, 2026. The FDA-cleared mechanical thrombectomy platform uses proprietary dual-basket technology and a nitinol collection funnel for non-surgical removal of thrombi and emboli from peripheral arteries. The acquisition expands Endologix's vascular intervention portfolio, complementing existing DETOUR, ALTO, and AFX2 platforms, and a core group of Surmodics employees supporting the Pounce platform will transition to Endologix.Pulse 2.0Endologix: Acquisition Of Pounce Thrombectomy System Expands Vascular Intervention PortfolioEndologix acquired the Pounce Thrombectomy System from Surmodics, a fully mechanical thrombectomy system for peripheral arteries. The acquisition expands Endologix's vascular intervention portfolio, complementing its DETOUR, ALTO, and AFX2 platforms. The system will continue under its existing FDA clearance during a transition period.VascularnewsEndologix acquires Pounce thrombectomy systemEndologix acquired the Pounce thrombectomy system from Surmodics, with the deal closing on 18 May 2026. The FDA-cleared system uses dual-basket technology for peripheral arterial thrombectomy. Endologix will market it under existing FDA clearance during a transition period.Medical Device NetworkEndologix purchases thrombectomy system from SurmodicsEndologix acquired Surmodics' Pounce mechanical thrombectomy system to expand its vascular intervention portfolio. The system, cleared by the FDA, is designed for non-surgical removal of thrombi and emboli from peripheral arteries. The acquisition adds a commercially available platform for clinical partners using Endologix's Detour, Alto, and AFX2 platforms.citybizEndologix Expands Peripheral Vascular Portfolio With Pounce Thrombectomy AcquisitionEndologix acquired the Pounce Thrombectomy System from Surmodics, expanding its vascular intervention portfolio with a fully mechanical clot-removal technology. The deal, closed on May 18, aims to enhance Endologix's offerings in minimally invasive treatments for arterial blockages and meet increasing demand for simpler, outpatient procedures.OcbjEndologix Acquires Pounce System from SurmodicsEndologix acquired the Pounce Thrombectomy System from Surmodics, an FDA-cleared device for non-surgical removal of thrombi and emboli from peripheral arteries. The acquisition expands Endologix's commercial offerings, which include Detour, Alto, and AFX2 platforms.